Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Cambridge Medical Robotics clears $46m series A

Cambridge Medical Robotics clears $46m series A

Sep 18, 2017 • Callum Cyrus

The surgery robotics developer has added $26m from investors including Cambridge Innovation Capital to complete its series A round, 14 months after closing the first tranche.

UK-based surgical robotics startup Cambridge Medical Robotics (CMR) closed a $46m series A round featuring Cambridge Innovation Capital (CIC), the patient capital fund founded by University of Cambridge, yesterday.

The round closed after CMR secured $26m from CIC, ABB Technology Ventures, a strategic investment subsidiary of power and automation group ABB, family-owned investment firm Watrium, Escala Capital and LGT Global Invest.

CIC, ABB Technology Ventures and LGT Global Invest had provided the initial $20.3m of series A funding for CMR in July 2016.

CMR has built a robotics system called Versius that can perform minimal access surgical procedures. It features a four-axis wrist joint to mimic the dexterity of a human surgeon and improve the robot’s ability to work within the smallest surgical incision.

Versius recently cleared a set of cadaveric trials that demonstrated its ability to conduct surgical procedures such as gynaecological or renal operations. The latest funds will be used to finish validation studies on a Versius prototype ahead of a planned production launch.

Martin Frost, chief executive of CMR, said: “Versius continues to demonstrate its leading position in this next generation of robotic surgery systems.

“I am pleased to report this significant progress and thank our existing and new investors for their enthusiastic support and look forward to continuing our rapid development as we lay the foundations for producing and marketing this in-demand system.”

– A version of this article first appeared on our sister site Global Corporate Venturing.

The surgery robotics developer has added $26m from investors including ABB Technology Ventures to complete its series A round, 14 months after closing the first tranche.

UK-based surgical robotics startup Cambridge Medical Robotics (CMR) closed a series A round featuring ABB Technology Ventures, a strategic investment subsidiary of power and automation group ABB, at $46m yesterday.

The round closed after CMR secured $26m from ABB Technology Ventures as well as Cambridge Innovation Capital (CIC), the university venture fund run by Cambridge University, family-owned investment firm Watrium, Escala Capital and LGT Global Invest.

ABB Technology Ventures, LGT Global Invest and CIC had provided the initial $20.3m of series A funding for CMR in July 2016.

CMR has built a robotics system called Versius that can perform minimal access surgical procedures. It features a four-axis wrist joint to mimic the dexterity of a human surgeon and improve the robot’s ability to work within the smallest surgical incision.

Versius recently cleared a set of cadaveric trials that demonstrated its ability to conduct surgical procedures such as gynaecological or renal operations. The latest funds will be used to finish validation studies on a Versius prototype ahead of a planned production launch.

Martin Frost, chief executive of CMR, said: “Versius continues to demonstrate its leading position in this next generation of robotic surgery systems.

“I am pleased to report this significant progress and thank our existing and new investors for their enthusiastic support and look forward to continuing our rapid development as we lay the foundations for producing and marketing this in-demand system.”

– This article was amended on September 20 to remove a quote from Girish Nadkarni, former president of ABB Technology Ventures, who has now moved to Total Energy Ventures.

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here